Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation Study of GC4419 in Combination With Radiation and Chemotherapy for Squamous Cell Cancers of the Head and Neck.

NCT01921426 is registered in ClinicalTrials.gov with Galera Therapeutics, Inc. as lead sponsor.

NCT NCT01921426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01921426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation Study of GC4419 in Combination With Radiation and Chemotherapy for Squamous Cell Cancers of the Head and Neck.
Lead sponsor
Galera Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2013
Completion date
August 31, 2016
Enrollment
30 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of the oral cavity, squamous cell carcinoma of the oropharynx